A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2.

Wong SK, Li W, Moore MJ, Choe H, Farzan M. · 2004

Read A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. by Wong SK, Li W, Moore MJ, Choe H, Farzan M. (2004) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7982343.txt.

Introduction

Wong and co-authors report a study pinning down the part of the SARS coronavirus spike that grips its receptor. The spike drives infection of cells that carry the receptor ACE2. It is also the main target of blocking antibodies. The team cut the spike into pieces and tested which piece binds ACE2 best. A clear winner emerged from the tests.

A fragment of 193 amino acids bound ACE2 more strongly than the whole outer domain. Smaller fragments failed to bind at all. One point change in the fragment killed the binding. The winning fragment also blocked infection at a far lower dose than the full domain. The results define a self-folding receptor-binding domain. That domain is the piece vaccine and drug work must target. The paper dates from the first SARS outbreak and still frames the field.

Catalog record

CREATORWong SK, Li W, Moore MJ, Choe H, Farzan M.
YEAR2004
COLLECTIONPAPERS
FORMATTXT
FILE SIZE25 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7982343

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

A 193-Amino Acid Fragment of the SARS Coronavirus S Protein Efficiently Binds Angiotensin-converting Enzyme 2* By Swee Kee Wong, Wenhui Li, Michael J Moore, Hyeryun Choe, Michael Farzan Published in: The Journal of Biological Chemistry DOI: 10.1074/jbc.C300520200 ABSTRACT Abstract The coronavirus spike (S) protein mediates infection of receptor-expressing host cells and is a critical target for antiviral neutralizing antibodies. Angiotensin-converting enzyme 2 (ACE2) is a functional receptor for the coronavirus (severe acute respiratory syndrome (SARS)-CoV) that causes SARS. Here we demonstrate that a 193-amino acid fragment of the S protein (residues 318–510) bound ACE2 more efficiently than did the full S1 domain (residues 12–672). Smaller S protein fragments, expressing residues 327–510 or 318–490, did not detectably bind ACE2. A point mutation at aspartic acid 454 abolished association of the full S1 domain and of the 193-residue fragment with ACE2. The 193-residue fragment blocked S protein-mediated infection with an IC50 of less than 10 nm, whereas the IC50 of the S1 domain was ∼50 nm. These data identify an independently folded receptor-binding domain of the SARS-CoV S protein. A distinct coronavirus (SARS-CoV)1 has been identified as the etiological agent of SARS, an acute pulmonary syndrome characterized by an atypical pneumonia that results in progressive respiratory failure and death in close to 10% of infected individuals (1, 2, 3, 4). SARS-CoV does not belong to any of the three previously defined genetic and serological coronavirus groups; the SARS-CoV S protein, a surface glycoprotein that mediates coronavirus entry into receptor-bearing cells, is also distinct from those of other coronaviruses (5, 6). Reflecting this difference, SARS-CoV does not utilize any previously identified coronavirus receptors to infect cells. Rather, as we have recently demonstrated, angiotensin-converting enzyme 2 (ACE2) serves as a functional receptor for this coronavirus (7). The S proteins of some coronaviruses, for example, that of mouse hepatitis virus (MHV), can be cleaved into two subunits (S1 and S2) (8, 9). The S proteins of other coronaviruses, such as those of human coronavirus 229E (HCoV-229E) and SARS-CoV, are not cleaved by the virus-producing cell (10). Nonetheless, S1 and S2 domains of these latter S proteins can be identified through their homology with the S1 and S2 subunits of cleaved coronavirus S proteins. The S1 domain of all characterized coronaviruses, including that of SARS-CoV, mediates an initial high affinity interaction with a cellular receptor (11, 12, 13). Independently folded receptor-binding domains of two coronaviruses have been described. The first 330 amino acids of the 769-residue S1 subunit of the MHV S protein is sufficient to bind carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1), the cellular receptor for MHV (13, 14, 15). A very different region of the S1 domain of HCoV-229E, between residues 407 and 547, is sufficient to associate with the cellular receptor for this coronavirus, aminopeptidase N (APN, CD13) (11, 12, 16). Here we show that a 193-amino acid fragment of the SARS-CoV S protein, residues 318–510, binds the SARS-CoV receptor ACE2 and blocks S protein-mediated infection more efficiently than does the full-length S1 domain. This region includes seven cysteines, five of which are essential for expression or ACE2 association. Point mutations within this domain, at glutamic acid 452 or aspartic acid 454, interfere with or abolish association with ACE2. These data identify a domain of the SARS-CoV S protein that may be a critical target for neutralizing antibodies against the virus. EXPERIMENTAL PROCEDURES Construction of S1-Ig, Truncation Variants, and Mutants—A plasmid encoding S1-Ig was generated by amplifying a region encoding residues 12–672 from an expression vector containing a codon-optimized form of the full-length S protein gene (7) and ligating this region into a previously described vector encoding the signal sequence of CD5 and the Fc domain of human IgG1 (17). Truncation variants were generated by inverse PCR amplification, using the S1-Ig plasmid as a template. Mutations within S1-Ig, or within a truncation mutant thereof expressing residues 318–510, were generated by site-directed mutagenesis using the QuikChange method (Stratagene). Two independent plasmids were generated for each variant, sequenced within their coding regions and assayed. Purification of S1 Protein Variants—293T cells were transfected with plasmids encoding S1-Ig or S1-Ig variants. One day post-transfection, cells were washed in PBS and subsequently incubated in 293 SFM II medium (Invitrogen). Medium was harvested after 48 h and proteins precipitated with protein A-Sepharose beads at 4 °C for 16 h. Beads were washed in PBS, 0.5 M NaCl, eluted with 50 mm sodium citrate/50 mm glycine (pH 2), and neutralized with NaOH. Purified proteins were concentrated with Centricon filters (Amicon) and dialyzed in PBS. Binding and Flow Cytometry—293T cells were transfected with a previously described plasmid encoding ACE2 (7) or with vector (pcDNA3.1, Invitrogen) alone. Three days post-transfection, cells were detached in PBS, 5 mm EDTA and washed with PBS, 0.5% BSA. S1-Ig or variants thereof were added to 106 cells to a final concentration of 250 nm, and the mixture was incubated on ice for 1 h. Cells were washed three times with PBS, 0.5% BSA, then incubated for 30 min on ice with anti-human IgG FITC conjugate (Sigma; 1:50 dilution). Cells were again washed with PBS, 0.5% BSA. Binding of IgG-tagged viral proteins to 293T cells transfected with ACE2-expressing plasmid was detected by flow cytometry. The mean value of the binding of S1-Ig or variants with the ACE2-transfected cells was subtracted from that of the mock-transfected cells and normalized to that of S1-Ig. Immunoprecipitation of Soluble ACE2—293T cells transfected with a previously described plasmid expressing soluble ACE2 (7) were metabolically labeled with [35S]cysteine and -methionine. Labeled medium was harvested 3 days post-transfection. 0.5 ml of soluble ACE2-containing medium was incubated for 15 min on ice with 25 pmol of purified S1-Ig or variants, to a final concentration of 50 nm. 20 μl of protein A-Sepharose was added to the mixture, which was then incubated for 1 h at room temperature. Protein A-Sepharose beads were washed three times with PBS, 0.1% Nonidet P-40 and once with PBS. Protein was analyzed by SDS-PAGE and quantified by phosphorimaging using ImageQuant software. Infection Assay with S Protein-Pseudotyped Virus—–293T cells were transfected with a plasmid encoding SARS-CoV S protein or VSV-G, together with a previously described plasmid encoding the genome of simian immunodeficiency virus (SIV), modified by deletion of the env gene and by replacement of the nef gene with that for green fluorescent protein (GFP) (18). Supernatants of transfected cells were harvested, and viral reverse transcriptase activity was measured. Supernatants containing S protein- or VSV-G-pseudotyped SIV were added to ACE2- or mock-transfected 293T cells in the presence or absence of the indicated concentrations of S1-Ig or of the 12–327 or 318–510 variants thereof. Media were changed the following day and GFP expression in infected cells was measured 2 days later by flow cytometry. RESULTS AND DISCUSSION A protein in which the S1 domain of the SARS-CoV S protein was fused to the Fc region of human IgG1 has been shown to associate with ACE2-expressing cells and to precipitate ACE2 (7). To identify the receptor-binding domain of the S protein, this fusion protein, S1-Ig, was sequentially deleted at the N and C termini of the S1 domain to make a total of 12 additional variants. Each variant expressed efficiently and could be

Read the complete text